SANUWAVE Q3 revenue up 19% to $5.0M; net loss $23.7M on non-cash derivative charges

SANUWAVE Health, Inc.

2023-Q3 EPS reported -$0.06 revenue$13,404,000

Revenue $5.0M (+19% YoY); UltraMist consumables +24% to $3.1M, 62% of revenue.
Operating loss improved to $0.5M from $2.5M YoY; adjusted EBITDA loss $0.3M vs $2.2M.
Net loss $23.7M vs $1.1M YoY, driven by non-cash fair value losses on derivative liabilities.
55 UltraMist systems sold in Q3 (up from 28 in Q1 and 49 in Q2).
Gross margin 71% vs 72% YoY, stable despite growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANUWAVE Health, Inc. reported the third quarter ended September 30, 2023 results: revenue $5.0 million, net income $23.7 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $5.0 million
Net income: $23.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

care products, today announced its 3rd quarter 2023 results. For the three months ended September 30, 2023: ■ Revenue for the three months ended September 30, 2023 totaled $5.0 million, an increase of 19%, as compared to $4.2 million for the same period of 2022. This growth falls within the previously provided guidance range of an approximately 15 to 25%

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-052959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.